EDITORIAL

Why create a new journal of dermatology in 1991?
Jean Thivolet

CLINICAL REPORTS

Primary cutaneous B-cell lymphoma as first manifestation of acquired immuno-deficiency syndrome

Acute monoblastic leukemia and histiocytosis X: a case report and review of the literature
F. Cambazard L. Misery J. Kanitakis E. Archimbaud C. Hermier

Acanthosis nigricans and insulin resistance in obese patients: a frequent but underestimated dermatoendocrinopathy
V. Martin Ch. Thivolet L. Bajard L. Thomas M. Faure

Occupational allergic contact dermatitis from iatrogenic sensitization by a new acrylate dentin adhesive
L. Kanerva K. Turjanmaa R. Jolanki T. Estlander

CASE REPORTS

Digital extraskeletal chondroma
A.L. Claudy W. Godard L. Jacquelin

Infundibular keratosis: a distinctive infundibular tumour
M.J. López Redondo C. Schoendorff L. Requena G. Roustan E. Sanchez Yus F. Sánchez de Paz

Polyeponychia bolboide: an unusual manifestation of factitious disorder?
R. Happle A. Chang

REVIEW ARTICLE

Skin ceramides: structure and function
M. Kerscher H.C. Korting M. Schäfer-Korting

INVESTIGATIVE REPORTS

Conversion of human epidermal Langerhans cells into interdigitating cells in vitro is not associated with functional maturation
M.B.M. Teunissen J. Wormmeester H.A.H. Rongen M.L. Kapsenberg J.D. Bos

Levels of immunoreactive interleukin 1α and β in basal, suprabasal and cornified epidermal cell subpopulations of normal human epidermis. Comparison with keratinocytes cultured in defined medium
H. Gatto J. Viac A. Reano M. Charveron

SHORT COMMUNICATION

Increased binding sites of dansylated cyclosporin A in psoriatic epidermis grafted onto nude mice during cyclosporin A treatment
A. Urabe J. Nakayama H. Terao Y. Ori

THESIS

Cyclosporin A in the treatment of psoriasis
F. Henle

Sensory neuromediators in human skin/role in inflammation and other disorders
J. Wallengren
Coincidence of increased soluble interleukin-2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T-cell lymphomas

In 24 patients with cutaneous T-cell lymphomas (CTCL) the clinical course was documented by determination of a tumour burden index (TBI) on entering the study and six months later. In addition to the first TBI, soluble interleukin-2 receptor levels (sIL-2R) in the serum were determined using an ELISA technique in 23 patients. In 18 patients natural killer cell (NK) activity was assessed by a 4 h chromium-51 release assay. Statistical analysis revealed a negative correlation between NK activity and an increase of TBI as well as NK activity and sIL-2R. Furthermore, there was a strong positive correlation between the increase of TBI and sIL-2R. sIL-2R and NK activity might be prognostic factors in CTCL patients.

Keywords: cutaneous T-cell lymphomas, soluble interleukin-2 receptor, natural killer cell activity, prognostic factors.

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphoproliferative disorders originating in the skin. In general, the term designates a clinically, histologically and phenotypically variable spectrum of diseases which are slowly progressive and show striking interindividual differences [1]. An increased risk of second malignancy [2] and a decrease in natural killer cell activity [3, 4] indicate imbalanced immunofunctions in these patients. Recently, we and others [5, 6] reported elevated serum levels of soluble interleukin-2 receptors (TAC-protein) in some of these patients. Yet, the biological relevance of this phenomenon is unclear.

In the present study we analysed the interactions of NK activity, sIL-2R and the clinical outcome in CTCL patients.
Table I. Patients characteristics: sIL-2R, NK activity, and clinical course described by △ TBI

<table>
<thead>
<tr>
<th>Pat.</th>
<th>Stage TNM[19]</th>
<th>Histol. diagnosis</th>
<th>Pretreatment</th>
<th>therapy during follow-up period (6 months)</th>
<th>sIL-2R (U/ml) (n = 23)</th>
<th>Spec. lysis (%) (n = 18)</th>
<th>△ TBI (n = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>IIA</td>
<td>low-grade peripheral</td>
<td>e.b.r.</td>
<td>e. ster.</td>
<td>1690</td>
<td>5.0</td>
<td>18</td>
</tr>
<tr>
<td>HE</td>
<td>IIB</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>385</td>
<td>13.0</td>
<td>5</td>
</tr>
<tr>
<td>WA</td>
<td>IA</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>405</td>
<td>16.5</td>
<td>0</td>
</tr>
<tr>
<td>BA</td>
<td>IIA</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>330</td>
<td>4.0</td>
<td>0</td>
</tr>
<tr>
<td>HO</td>
<td>IIB</td>
<td>high-grade peripheral</td>
<td>MTX, IFN-α</td>
<td>MTX, e. ster.</td>
<td>538</td>
<td>30.7</td>
<td>0</td>
</tr>
<tr>
<td>ST</td>
<td>IIB</td>
<td>low-grade peripheral</td>
<td>BCNU, topical</td>
<td>BCNU topical</td>
<td>3000</td>
<td>6.4</td>
<td>30</td>
</tr>
<tr>
<td>TI</td>
<td>III</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>BCNU topical</td>
<td>1320</td>
<td>4.0</td>
<td>12</td>
</tr>
<tr>
<td>KA</td>
<td>IIA</td>
<td>low-grade peripheral</td>
<td>e. ster., IFN-α</td>
<td>e. ster.</td>
<td>3570</td>
<td>6.0</td>
<td>20</td>
</tr>
<tr>
<td>KAI</td>
<td>IIB</td>
<td>high-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>e. ster.</td>
<td>10700</td>
<td>6.0</td>
<td>20</td>
</tr>
<tr>
<td>KE</td>
<td>IIA</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>1190</td>
<td>21.9</td>
<td>20</td>
</tr>
<tr>
<td>SCH</td>
<td>IA</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>950</td>
<td>10.5</td>
<td>0</td>
</tr>
<tr>
<td>HO</td>
<td>IIB</td>
<td>high-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>e. ster., MTX</td>
<td>9230</td>
<td>n.d.</td>
<td>40</td>
</tr>
<tr>
<td>RE</td>
<td>IIA</td>
<td>high-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>720</td>
<td>15.0</td>
<td>0</td>
</tr>
<tr>
<td>TR</td>
<td>IA</td>
<td>low-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>IFN-α, e. ster.</td>
<td>800</td>
<td>42.3</td>
<td>0</td>
</tr>
<tr>
<td>GEL</td>
<td>IIB</td>
<td>high-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>570</td>
<td>n.d.</td>
<td>0</td>
</tr>
<tr>
<td>BET</td>
<td>IIA</td>
<td>low-grade peripheral</td>
<td>none</td>
<td>PUVA</td>
<td>7330</td>
<td>2.3</td>
<td>20</td>
</tr>
<tr>
<td>HER</td>
<td>IA</td>
<td>low-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>e. ster.</td>
<td>1110</td>
<td>6.9</td>
<td>0</td>
</tr>
<tr>
<td>KÜ</td>
<td>IB</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>e. ster.</td>
<td>650</td>
<td>24.7</td>
<td>2</td>
</tr>
<tr>
<td>VA</td>
<td>IIB</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>prednimustine</td>
<td>300</td>
<td>22.5</td>
<td>0</td>
</tr>
<tr>
<td>GR</td>
<td>IA</td>
<td>low-grade peripheral</td>
<td>e. ster.</td>
<td>BCNU topical</td>
<td>790</td>
<td>n.d.</td>
<td>0</td>
</tr>
<tr>
<td>DO</td>
<td>IVA</td>
<td>low-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>e. ster.</td>
<td>12300</td>
<td>n.d.</td>
<td>40</td>
</tr>
<tr>
<td>KUN</td>
<td>IVA</td>
<td>low-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>e. ster.</td>
<td>1190</td>
<td>n.d.</td>
<td>40</td>
</tr>
<tr>
<td>YI</td>
<td>IA</td>
<td>low-grade peripheral</td>
<td>PUVA, e. ster.</td>
<td>e. ster.</td>
<td>510</td>
<td>n.d.</td>
<td>0</td>
</tr>
<tr>
<td>WAL</td>
<td>IA</td>
<td>high-grade peripheral</td>
<td>none</td>
<td>e. ster.</td>
<td>n.d.</td>
<td>19.8</td>
<td>0</td>
</tr>
</tbody>
</table>


Patients and methods

Patients
Twenty four patients with histologically proven CTCL in different stages were investigated. Before entering the study, systemic treatment had been stopped for at least two weeks. Physical examinations were done on day 0 and repeated six months later (for all 24 patients). Staging procedures and histological classification were done according to the recommendations for staging and therapy of cutaneous lymphomas of the European Organization for Research and Treatment of Cancer, cutaneous lymphoma project group [7]. On day 0, peripheral blood mononuclear cells for 51Cr release assay were taken in 18 patients, and serum samples were collected in 23 patients. Patients' characteristics including pretreatment and therapy during the follow-up period are summarized in Table I. Therapy in the follow-up period was applied according to the clinical necessities.
Clinical course
In order to estimate the cutaneous tumour mass in a semiquantitative manner, a tumour burden index was introduced. Physical examinations were done by one investigator, only. The percentage of involved skin was documented using the rule of the nines. Specific skin lesions were differentiated in patches (flat lesions, diameter larger than 1 cm), plaques (flat or slightly elevated lesions with increased consistency) and tumours (large nodular lesions, diameter larger than 1 cm) [7]. The extension of tumours, patches and plaques was noted and the tumour burden index (TBI) was calculated as:

<table>
<thead>
<tr>
<th>tumour plaque patch</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBI = x% \times 4 + x% \times 2 + x% \times 1</td>
</tr>
</tbody>
</table>

x% = involved skin in %

Under these conditions the maximal achievable TBI was 400. In our patients the TBI was 41 ± 59 (mean ± standard deviation, minimal 2, maximal 280).

The clinical course of progressing patients was determined by the difference of the tumour burden index (ΔTBI) at day 0 and six months later. It was calculated as:

ΔTBI = TBIₐ₋ TBI₀;
TBIₐ = after six months, TBI₀ = TBI day 0.

Patients with a stable disease or regression of tumours had a ΔTBI ≤ 0. A strong positive correlation was found between sIL-2R and ΔTBI (r = -0.3492, P < 0.05).

Soluble interleukin-2 receptors
Soluble interleukin-2 receptors (sIL-2R) in the serum were determined by sandwich ELISA (T Cell Sciences Inc., Cambridge, USA) [8]. The test employs two non-competing murine monoclonal antibodies to the α-chain of human IL-2R. It was done according to the manufacturer's instructions. The microfiter plates were read at 490 nm using a Dynatech MR 700 microplate reader. Units of sIL-2R were calculated from a standard curve constructed on the basis of a supernatant from phytohemagglutinin-stimulated peripheral blood mononuclear cells. Interassay variation was 5%.

Natural killer cell activity
Peripheral mononuclear cells (PMC) were separated by Ficoll-Hypaque centrifugation. NK activity was determined in a 4 h ⁵¹Cr release assay as previously described [9], using the NK-sensitive erythroblastoma cell line K562 as target cells. The effector:target ratio was 40:1. Spontaneous release was assessed by incubating labelled K 562 in medium alone, and total release was evaluated by a solution of SDS. After harvesting the supernatants using a Skatron filterstick system, radioactivity was measured in a Pharmacia gamma-counter. Specific lysis (SL) was calculated as:

\[ SL(\%) = \frac{\text{Mean experimental release} - \text{mean spontaneous release}}{\text{Mean total release} - \text{mean spontaneous release}} \times 100 \]

Statistical tests
A computerized correlation analysis was performed using a new statistical program (MEDAS) developed by Grund C., Haubitz I. and Rausche A. Institute for Biostatistics, University of Würzburg. Correlation between sIL-2R and NK activities was analysed by the calculation of Spearman’s correlation coefficient, p. Correlation between ΔTBI and sIL-2R and NK activity, respectively, was determined by the calculation of Kendal’s correlation coefficient, r.

Results
The results of sIL-2R, NK activity and clinical course are summarized in Table I. Statistical analysis of our data revealed correlations between NK activity, sIL-2R and disease progression, which was described by the ΔTBI. There was a negative correlation between NK activity and ΔTBI (r = -0.3492, P < 0.05). A strong positive correlation was found between sIL-2R and ΔTBI (r = 0.6091, P < 0.0005). No correlation between staging and sIL-2R or staging and NK activity was observed. NK activity and sIL-2R showed a negative correlation (r = -0.5423, P < 0.03).

Analysing the reliability of sIL-2R as a prognostic factor, we suggest that a ΔTBI of at least 10 should be considered as a significant change. Moreover, sIL-2R should exceed the upper normal range by a factor of 2 (> 1000 U/ml). Under these conditions the specificity of sIL-2R for tumour progression was 90.0% (n = 11). There was no false-positive value, indicating high sensitivity (Fig. 1).

Discussion
Recent reports of successful transplantation of cutaneous lymphomas on natural killer cell-depleted severe combined immunodeficient (SCID) mice [10] as well as...
as an enhanced risk of developing secondary neoplasias [2] point to impaired immunofunctions in CTCL patients. Analysing NK activity and clinical course in these patients we found a correlation between the decrease of NK activity and the progression of the disease. We conclude that NK activity might be a prognostic factor for CTCL patients. Elevated levels of sIL-2R were found in the serum of patients suffering from lymphoproliferative disorders [5, 6, 11, 12] as well as in the serum of patients suffering from inflammatory skin diseases [13].

Regarding the strong correlation between tumour progression in CTCL patients and sIL-2R, we suggest that this soluble protein may be of high prognostic value. This is consistent with the detection of sIL-2R as an unfavourable prognostic sign in other lymphoproliferative disorders such as Hodgkin’s disease [11] and lymphoblastic lymphomas [12]. From an immunological point of view, the negative correlation between sIL-2R and NK activities offers interesting perspectives. Under physiologic circumstances, membrane-bound and soluble forms of the TAC protein are observed after T-cell stimulation, for example by antigen presenting cells and interleukin 1. As a consequence, the stimulated T lymphocytes produce interleukin-2 [14]. In CTCL patients this mechanism seems to be disturbed. In some CTCL patients, interleukin 1 [15] might enhance expression of TAC protein, albeit, without additional induction of interleukin-2, which is able to restore diminished NK activity [16] and is known to be a potent stimulating cytokine for NK activity [9]. This discordance could be an important factor for tumour spreading. We propose, that sIL-2R might be responsible for the decreased NK activity by neutralizing interleukin-2 [17, 18].

References

Abbreviations
CTCL: cutaneous T-cell lymphoma.
SCID: severe combined immune deficiency.
sIL-2R: soluble interleukin-2 receptor.
NK: natural killer cell.
TBI: tumour burden index.

Zusammenfassung
Bei 24 Patienten mit cutanem T-Zell Lymphom (CTCL) wurde der klinische Verlauf mittels eines "Tumor burden index (TBI)" bei Beginn der Beobachtung und sechs Monate später dokumentiert. Zusammen mit dem ersten TBI wurde der lösliche Interleukin-2 Rezeptor (sIL-2R) im Serum mittels ELISA und die natürliche Killerzelle (NK-) Aktivität der peripheren mononukleären Zellen mittels "Cr-51 Release Assay" bestimmt. Die statistische Auswertung der drei Parameter ergab eine negative Korrelation zwischen NK-Aktivität und Zunahme des TBI, sowie zwischen NK-Aktivität und sIL-2R. Außerdem fand sich eine hochsignifikante Korrelation zwischen sIL-2R und Zunahme des TBI. sIL-2R und NK-Aktivität sind möglicherweise von prognotischer Bedeutung bei Patienten mit CTCL.

European Cytokine Network
Number of issues: 6
Subscriptions can be paid by check made out to European Cytokine Network. Orders for subscription should be filled out and sent, together with the check and signature, to: John Libbey Eurotext, 6, rue Blanche - 91210 Montrouge, France. Tel.: (33.1) 47.35.85.52
Telefax: (33.1) 46.57.10.09

Inquiries
All questions concerning subscriptions and mailing should be sent to the above address.

Subscription rates
<table>
<thead>
<tr>
<th>France</th>
<th>Rest of Europe</th>
<th>Rest of World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual</td>
<td>800 FF</td>
<td>US $ 135</td>
</tr>
<tr>
<td>Institutional</td>
<td>1,000 FF</td>
<td>US $ 180</td>
</tr>
<tr>
<td>Students</td>
<td>500 FF</td>
<td>US $ 90</td>
</tr>
</tbody>
</table>

Prices are for a one-year subscription (1 volume of 6 issues) and include postage and handling charges. Advertising rates available on request.